Skip to main content
Medical information Clinical review pending

Genetic Testing

Nx Gen Sequencing Alexander Disease Test

Advanced genetic test using Next-Generation Sequencing (NGS) to identify mutations in the GFAP gene associated with Alexander Disease, a rare neurological disorder.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
10 mL (5 mL minimum) of whole blood collected in two Lavender Top (EDTA) tubes.
Results
Results are typically available within 40 working days. Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the sample is collected in the correct tubes as specified.
Test priceKSh 46,800

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Nx Gen Sequencing Alexander Disease Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Severe and progressive spasticity
  • ✓Recurrent seizures
  • ✓Developmental delays
  • ✓Neurological decline
  • ✓Family history of Alexander Disease or related neurological disorders
02

In plain language

What this test helps you understand

This test helps confirm a diagnosis of Alexander Disease by identifying mutations in the GFAP gene. It can guide treatment decisions, inform prognosis, and provide valuable information for genetic counseling and family planning.
The Nx Gen Sequencing Alexander Disease Test is an advanced molecular diagnostic tool designed to detect genetic mutations linked to Alexander Disease. This rare neurological condition primarily affects infants and young children, often causing severe symptoms like spasticity and seizures. Early and accurate diagnosis is vital for managing the condition effectively. This test utilizes Next-Generation Sequencing (NGS) and Sanger sequencing to analyze the GFAP gene, the primary gene associated with Alexander Disease. It provides comprehensive genetic insights relevant to the condition. Discuss the test with your doctor to determine if it's appropriate for you or your child.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the sample is collected in the correct tubes as specified.
Sample10 mL (5 mL minimum) of whole blood collected in two Lavender Top (EDTA) tubes.
MethodologyNext-Generation Sequencing (NGS) and Sanger sequencing are used to analyze the GFAP gene for mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically targets mutations in the GFAP gene. It may not detect all possible genetic causes of similar symptoms. Results should be interpreted in the context of clinical findings and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Alexander Disease is a rare genetic neurological disorder that primarily affects the brain's white matter, often leading to severe symptoms in infants and young children.
Individuals, especially children, experiencing symptoms like severe spasticity, seizures, developmental delays, or neurological decline should discuss this test with their doctor.
The test requires a blood sample collected in two Lavender Top (EDTA) tubes. We offer home sample collection services.
Results are generally available within 40 working days. Confirm with the laboratory before booking.
A positive result indicates the presence of mutations in the GFAP gene associated with Alexander Disease, confirming the diagnosis.
Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific genetic test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp